BofA/Merrill Restarts Gilead at Buy; Amgen, Celgene at Neutral; Biogen at Underperform (GILD, AMGN, CELG, BIIB)
Tweet Send to a Friend
An analyst at BofA/Merrill reinstated several Biotech and Drug stocks this morning:
This article: 60 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 60 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
